[1]乔瑞,姜祎群.常见分子靶向抗肿瘤药物皮肤不良反应及诊治的研究进展[J].中国皮肤性病学杂志,2021,(09):1054-1058.[doi:10.13735/j.cjdv.1001-7089.202006008]
 QIAO Rui,JIANG Yiqun.Progress on Cutaneous Adverse Events and Management of Common Molecular Targeted Anti-tumor Drugs[J].The Chinese Journal of Dermatovenereology,2021,(09):1054-1058.[doi:10.13735/j.cjdv.1001-7089.202006008]
点击复制

常见分子靶向抗肿瘤药物皮肤不良反应及诊治的研究进展()
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2021年09期
页码:
1054-1058
栏目:
综述
出版日期:
2021-09-01

文章信息/Info

Title:
Progress on Cutaneous Adverse Events and Management of Common Molecular Targeted Anti-tumor Drugs
文章编号:
1001-7089(2021)09-1054-05
作者:
乔瑞姜祎群
中国医学科学院北京协和医学院皮肤病研究所,江苏 南京 210042
Author(s):
QIAO Rui JIANG Yiqun
(Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing 210042, China)
关键词:
分子靶向药物 抗肿瘤药物 皮肤不良反应 临床诊疗
Keywords:
Molecular targeted drugs Anti-tumor drugs Cutaneous adverse reactions Clinical treatment
分类号:
R 979.1
DOI:
10.13735/j.cjdv.1001-7089.202006008
文献标志码:
A
摘要:
近年来,分子靶向抗肿瘤药物在肿瘤内科领域中发挥着重要作用。根据药物作用靶点不同,具体可分为表皮生长因子受体抑制剂(epidermal growth factor receptor inhibitors,EGFRIs)、酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)、BRAF抑制剂、免疫检查点抑制剂等。不同种类药物诱发的皮肤不良反应谱有重叠,也有各自特殊表现。治疗原则依据皮损的严重程度,轻中度皮损仅对症处理,重度皮损应减药或停药。本文对分子靶向抗肿瘤药物所引起临床常见的皮肤相关不良反应及治疗进展进行综述。
Abstract:
In recent years, molecular targeted antitumor drugs have played an important role in the field of medical oncology.Based on different targets, these drugs can be classified into epidermal growth factor receptor inhibitors(EGFRIs), tyrosine kinase inhibitors(TKIs), BRAF inhibitors, and immune checkpoint inhibitors.The spectrum of cutaneous adverse reactions induced by different kinds of drugs partially overlaps, and also has their own special manifestations.Treatment depends on the severity of skin lesions.For mild to moderate skin lesions, symptomatic treatment is enough.And the antitumor drugs need dose-reduced or discontinued if severe skin lesions presented.This article has reviewed the common clinical cutaneous adverse reactions of molecular targeted antitumor drugs and the management.

参考文献/References:

[1] Barton-Burke MCK, Mekas M, Burke S.Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care[J].Nurs Clin North Am, 2017, 52(1): 83-113.
[2] Nakahara T, Moroi Y, Takayama K, et al.Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors[J].Onco Targets Ther, 2015, 8: 259-263.
[3] Peng Y, Li Q, Zhang J, et al.Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors[J].Biosci Trends, 2019, 12(6): 537-552.
[4] Pugliese SB, Neal JW, Kwong BY.Management of Dermatologic complications of lung cancer therapies[J].Curr Treat Options Oncol, 2015, 16(10):50.
[5] McLellan B, Kerr H.Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib[J].Dermatol Ther, 2011, 24(4): 396-400.
[6] Massey PR, Okman JS, Wilkerson J, et al.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor(VEGFR)have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature[J].Support Care Cancer, 2015, 23(6): 1827-1835.
[7] Zimmerman EI, Gibson AA, Hu S, et al.Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death[J].Cancer Res, 2016, 76(1): 117-126.
[8] Pichard DC, Cardones AR, Chu EY, et al.Sorafenib-induced eruption mimicking erythema multiforme[J].JAMA Dermatol, 2016, 152(2): 227-228.
[9] Gnanendran SS, Turner LM, Miller JA, et al.Cutaneous adverse events of anti-PD-1 therapy and BRAF inhibitors[J].Curr Treat Options Oncol, 2020, 21(4): 29.
[10] Lacouture M, Sibaud V.Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails[J].Am J Clin Dermatol, 2018, 19(Suppl 1): 31-39.
[11] Hawerkamp HC, Kislat A, Gerber PA, et al.Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events[J].Allergy, 2019, 74(12): 2437-2448.
[12] Carlos G, Anforth R, Clements A, et al.Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma[J].JAMA Dermatol, 2015, 151(10): 1103-1109.
[13] Negulescu M, Deilhes F, Sibaud V, et al.Panniculitis associated with MEK inhibitor therapy: an uncommon adverse effect[J].Case Rep Dermatol, 2017, 9(1): 80-85.
[14] Hassel JC, Heinzerling L, Aberle J, et al.Combined immune checkpoint blockade(anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions[J].Cancer Treat Rev, 2017, 57: 36-49.
[15] Li AW KC, Leventhal JS.Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab[J].Eur J Dermatol, 2017, 27(3): 325-326.
[16] Matsumoto Y, Kadono T, Matsuoka M, et al.Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy[J].J Dermatol, 2018, 45(2): e33-e34.
[17] Kato Y, Otsuka A, Miyachi Y.Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma[J].J Eur Acad Dermatol Venereol, 2016, 30(10): e88-e89.
[18] Voudouri D, Nikolaou V, Laschos K, et al.Anti-PD1/PDL1 induced psoriasis[J].Curr Probl Cancer, 2017, 41(6): 407-412.
[19] Sun X, Roudi R, Dai T, et al.Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis[J].BMC Cancer, 2019, 19(1): 558.
[20] Tanaka R, Okiyama N, Okune M, et al.Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-alpha is a biomarker of nivolumab recativity[J].J Dermatol Sci, 2017, 86(1): 71-73.
[21] Lopez AT, Geskin L.A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management[J].Oncologist, 2018, 23(10): 1119-1126.
[22] Parakh S, Nguyen R, Opie JM, et al.Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma[J].Australas J Dermatol, 2017, 58(3): e109-e112.
[23] Teng Y, Guo RF, Sun JF, et al.Reactive capillary hemangiomas induced by camrelizumab(SHR-1210), an anti-PD-1 agent[J].Acta Oncologica, 2019, 58(3): 388-389.
[24] Wang F, Qin S, Sun X, et al.Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J].J Hematol Oncol, 2020, 13(1): 47.
[25] Nomura H, Takahashi H, Suzuki S, et al.Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy[J].J Dermatol, 2017, 44(7): 818-821.
[26] 中国抗癌协会肺癌专业委员会. EGFR-TKI不良反应管理专家共识[J].中国肺癌杂志, 2019, 22(2): 57-81.
[27] Nakamura Y, Tanaka R, Asami Y, et al.Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study[J].J Dermatol, 2017, 44(2): 117-122.
[28] Larsabal M, Marti A, Jacquemin C, et al.Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo[J].J Am Acad Dermatol, 2017, 76(5):863-870.
[29] Sollena P, Mannino M, Tassone F, et al.Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature[J].Drugs Context, 2019, 8: 212613.

备注/Memo

备注/Memo:
[基金项目] 中国医学科学院医学与健康科技创新工程项目(CIFMS-2017-I2M-1-017)
[通信作者] 姜祎群,E-mail:yiqunjiang@qq.com
更新日期/Last Update: 2021-09-01